C-Peptide : Proinsulin-Derived Signaling Molecule, Microvascular Protection, and Metabolic Regulatory Research in Diabetes Models

C-peptide (connecting peptide) is a 31-amino acid polypeptide that is secreted from pancreatic beta cells in equimolar amounts with insulin. Discovered in 1967 by Donald Steiner, C-peptide was initially considered biologically inert, serving merely as a structural linker facilitating the correct folding of proinsulin into its bioactive tertiary structure. For decades, its clinical utility was limited to its role as a diagnostic biomarker for endogenous insulin secretion, given its negligible hepatic extraction and longer half-life compared to insulin. However, this paradigm has shifted dramatically over the last twenty years. Extensive research has now elucidated that C-peptide is a bioactive peptide with specific physiological effects, particularly regarding microvascular function and nerve integrity. In patients with type 1 diabetes, the complete absence of C-peptide contributes to the development of long-term complications such as nephropathy, neuropathy, and retinopathy. Studies demonstrate that C-peptide replacement in diabetic animal models and human trials ameliorates these complications by targeting intracellular signaling pathways distinct from those activated by insulin. Specifically, C-peptide has been shown to stimulate Na+/K+-ATPase activity, enhance endothelial nitric oxide synthase (eNOS) transcription, and activate the MAPK signaling cascade. The recognition of C-peptide as a hormone in its own right has opened new avenues for therapeutic research. It represents a missing link in the physiological replacement of beta-cell secretory products. While insulin therapy addresses glycemic control, it does not correct the signaling deficits caused by C-peptide deficiency. Current investigation is focused on understanding the molecular mechanisms of C-peptide action, identifying its putative G-protein coupled receptor (GPCR), and determining its potential role in preventing or reversing the devastating microvascular sequelae of diabetes mellitus. MOLECULAR STRUCTURE AND PROINSULIN PROCESSING C-peptide is generated during the proteolytic processing of proinsulin within the secretory granules of pancreatic beta cells. The proinsulin molecule consists of the B-chain, the C-peptide linker, and the A-chain. The 31-amino acid sequence of human C-peptide (Glu-Ala-Glu-Asp-Leu-Gln-Val-Gln-Leu-Pro-Gly-Gly-Pro-Gly-Ser-Pro-Gln-Asp-Leu-Leu-Arg-Thr-Val-Glu-Gly-Leu-Ala-Gln-Glu) connects the C-terminus of the B-chain to the N-terminus of the A-chain, ensuring the formation of proper disulfide bonds. “The primary function of the C-peptide domain within the proinsulin molecule is to facilitate the correct folding architecture, allowing the cysteines of the A and B chains to align for disulfide bridge formation. Once this conformation is achieved, specific endopeptidases (PC1/3 and PC2) cleave the C-peptide at dibasic residues. The resulting products—mature insulin and free C-peptide—are stored in hexameric crystals stabilized by zinc ions. Upon glucose stimulation, these granules undergo exocytosis, releasing insulin and C-peptide into the portal circulation in a 1:1 molar ratio. While 50% of insulin is extracted by the liver during the first pass, C-peptide undergoes negligible hepatic clearance, making peripheral C-peptide levels a more accurate reflection of beta-cell secretory activity.” (1) The structural integrity of C-peptide is highly conserved among mammalian species, particularly in the N-terminal and C-terminal regions, suggesting functional importance beyond structural scaffolding. The presence of specific acidic residues allows C-peptide to interact with cell membranes, a property critical for its biological activity. Furthermore, its co-secretion with zinc ions has implications for amyloid formation and oligomerization, which are relevant to islet pathology in type 2 diabetes. “Unlike insulin, which has a circulatory half-life of 3-5 minutes, C-peptide persists in plasma for approximately 20-30 minutes. This pharmacokinetic difference is attributed to the fact that C-peptide is primarily cleared by the kidneys rather than the liver. In research settings, this property allows C-peptide to serve as a stable surrogate marker for insulin release, particularly in patients treated with exogenous insulin where endogenous insulin levels are obscured. More importantly, this longer residence time may allow C-peptide to exert sustained signaling effects on peripheral tissues, particularly the renal endothelium and nerve fibers.” (2) G-PROTEIN COUPLED RECEPTOR BINDING AND INTRACELLULAR SIGNAL TRANSDUCTION The mechanism by which C-peptide exerts its biological effects has been a subject of intense debate. While a specific C-peptide receptor has not been fully cloned, substantial evidence points to a specific G-protein coupled receptor (GPCR) mechanism. Binding studies on human cell membranes indicate saturable, high-affinity binding sites specific for C-peptide, distinct from the insulin and IGF-1 receptors. “The spe

For research use only. Not for human consumption.